CASP3 and colorectal carcinoma: We also observed a statistically significant increase in serum caspase 3/7 activity levels in CRC and sarcoma patients 24 h post dulanermin treatment in the first treatment cycles, suggesting a biological effect induced by dulanermin in cancer patients.